Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Apr 19, 2005 NEW HAVEN, CT April 19, 2005 - ZIOPHARM, Inc. announced today Dr. Lee Roy Morgan presented the preclinical pharmacology and toxicology data for ZIO-201 (L-IPM , or lysine-isophosphoramide mustard) at the American Association for Cancer Research (AACR) meeting in Anaheim, California. ZIO-201 is the Company's proprietary alkylating drug and the...
PDF
Apr 5, 2005 NEW HAVEN, CT April 5, 2005 - ZIOPHARM, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug Application (IND) for the clinical development of its proprietary organic arsenic compound, ZIO-101. The Company plans to initiate a dose-ranging Phase I trial of ZIO-101 in patients with hema...
PDF
Jan 7, 2005 NEW HAVEN, CT JAN. 7 - ZIOPHARM, Inc. announced today that it has entered into a two-year research Collaboration Agreement with the Southern Research Institute of Birmingham, Alabama to develop a series of IPM (isophosphoramide mustard) analogs. In conjunction with the research agreement, ZIOPHARM also signed a two-year Option Agreement to en...
PDF
Dec 6, 2004 SAN DIEGO, DEC. 6 -- ZIOPHARM, Inc. today announced that Dr. Xiaodong Cheng, MD from The University of Texas M.D. Anderson Cancer Center presented preclinical data on ZIO-102, the second of the Company's organic arsenic products. Data were presented at the 46th Annual Meeting of the American Society of Hematology (ASH), December 3-8, in San Di...
PDF
Nov 10, 2004 NEW HAVEN, CT NOVEMBER 10 - ZIOPHARM, Inc. announced it has secured an exclusive worldwide license to a novel and proprietary form of isophosphoramide mustard (IPM) from DEKK-TEC, Inc. of New Orleans. The new compound, ZIO-201, is currently in a Phase I clinical trial at the Karmanos Cancer Institute at Wayne State University in Michig...
PDF
Oct 26, 2004 NEW HAVEN, CT. OCT. 26 - ZIOPHARM, Inc. announced it received a Notice of Allowance from the US Patent and Trademark Office for US Patent Application No. 10/337969 titled "S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(simethylarsino) glutathione as treatments for cancer." The patent application claims both ...
PDF
Sep 20, 2004 NEW HAVEN, CT SEPT 20 - ZIOPHARM today announced that Dr. Srdan Verstovsek, MD, and his colleagues at The University of Texas M. D. Anderson Cancer Center reported mouse study data on the company's lead compound, ZIO-101, showing they were able to increase the arsenic dose 30-to-50-fold over that of inorganic arsenic without experiencing any se...
PDF
Sep 15, 2004 NEW HAVEN, CT SEPT 15 - Privately held ZIOPHARM, Inc., a developer of cancer drugs, announced it named eight individuals with diverse backgrounds in medicine, pharmaceutical and biotechnology management, legal and government affairs, and finance and communications to its board of directors under the leadership of Chief Executive Officer Jonatha...
PDF
Sep 15, 2004 NEW HAVEN, CT SEPT 15 - Privately-held ZIOPHARM, Inc. announced it completed a worldwide licensing agreement with The University of Texas M. D. Anderson Cancer Center and Texas A&M University for a new class of organic arsenicals, and said it plans to develop them for a wide range of cancers. The original synthesis of this class of organic arse...
PDF
Sep 14, 2004 NEW HAVEN, CT SEPTEMBER 14 - Newly formed and privately held ZIOPHARM, Inc., headed by chief executive officer Jonathan J. Lewis, MD, PhD announced the members of its senior management team whose positions are effective immediately. "This is a 'Dream Team' for a cancer products company," said Dr. Lewis, former chief medical officer of ...
PDF
Page: FirstPrevious ...
42
NextLast